• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

    6/9/25 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care
    Get the next $AEMD alert in real time by email

    Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples

    SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 (https://www.keystonesymposia.org/conferences/conference-listing/meeting/program-highlights/F12026).

    Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective.

    Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID.  EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation.

    Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose.

    The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered  from COVID-19 in order to examine whether  individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively.

    Presentation details and times are as follows:

    Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® 

    Authors: Miguel Pesqueira1, Rosalia de Necochea Campion1, Thomas Dalhuisen2, Emily A. Fehrman2, Jeffrey N. Martin2, Timothy J. Henrich2, Steven G. Deeks2, Michael J. Peluso2, Steven P. LaRosa1

    1. Aethlon Medical Inc., San Diego, CA, USA
    2. University of California, San Francisco, San Francisco, CA, USA

    Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Inc.

    Poster Number: 2001

    Date and Time: August 12, 2025, 1930, MDT.

    This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at https://www.aethlonmedical.com/.

    About Aethlon and the Hemopurifier®

    Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

    Additional information can be found at www.AethlonMedical.com.

    Company Contact:

    Jim Frakes

    Chief Executive Officer and Chief Financial Officer

    Aethlon Medical, Inc.

    [email protected]

    Investor Contact:

    Susan Noonan

    S.A. Noonan Communications, LLC

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-new-pre-clinical-data-at-the-keystone-symposium-on-long-covid-and-other-post-acute-infection-syndromes-302475948.html

    SOURCE Aethlon Medical, Inc.

    Get the next $AEMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AEMD

    DatePrice TargetRatingAnalyst
    7/7/2025$1.50Neutral
    H.C. Wainwright
    6/25/2021$5.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEMD
    SEC Filings

    See more
    • Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AETHLON MEDICAL INC (0000882291) (Filer)

      6/27/25 1:04:24 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Aethlon Medical Inc.

      10-K - AETHLON MEDICAL INC (0000882291) (Filer)

      6/26/25 5:10:22 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical Inc. filed SEC Form 8-K: Other Events

      8-K - AETHLON MEDICAL INC (0000882291) (Filer)

      6/5/25 8:30:54 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Broenniman Edward G covered exercise/tax liability with 893 shares, decreasing direct ownership by 4% to 21,825 units (SEC Form 4)

      4 - AETHLON MEDICAL INC (0000882291) (Issuer)

      7/1/25 4:03:08 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Director Shah Chetan covered exercise/tax liability with 1,786 shares, decreasing direct ownership by 8% to 19,993 units (SEC Form 4)

      4 - AETHLON MEDICAL INC (0000882291) (Issuer)

      7/1/25 4:03:05 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Director Gikakis Nicolas covered exercise/tax liability with 1,786 shares, decreasing direct ownership by 8% to 20,004 units (SEC Form 4)

      4 - AETHLON MEDICAL INC (0000882291) (Issuer)

      7/1/25 4:03:06 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

       Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments.  Key Fiscal 2025 Highlights First three patients treated in Hemopurifier® cancer trial at Australian sitesIndian

      6/26/25 4:15:00 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

      SAN DIEGO, June 20, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal fourth quarter ended March 31, 2025, at 4:15 p.m. ET on Thursday, June 26, 2025. Management will host a conference call on Thursday, June 26, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10200578/ff60012c0c. P

      6/20/25 8:01:00 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial

      Second Patient in first cohort enrolled and treated at the Royal North Shore Hospital/University of Sydney Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, June 18, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the second patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 mon

      6/18/25 8:01:00 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

      H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

      7/7/25 8:15:50 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously

      6/25/21 6:10:29 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target

      HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00

      6/1/21 8:48:18 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)

      SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

      1/13/22 10:30:14 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Aethlon Medical, Inc.

      SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)

      6/15/21 10:01:32 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

      2/22/21 9:53:48 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care

    $AEMD
    Financials

    Live finance-specific insights

    See more
    • Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

       Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments.  Key Fiscal 2025 Highlights First three patients treated in Hemopurifier® cancer trial at Australian sitesIndian

      6/26/25 4:15:00 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

      SAN DIEGO, June 20, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal fourth quarter ended March 31, 2025, at 4:15 p.m. ET on Thursday, June 26, 2025. Management will host a conference call on Thursday, June 26, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10200578/ff60012c0c. P

      6/20/25 8:01:00 AM ET
      $AEMD
      Medical/Dental Instruments
      Health Care
    • Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

      Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Australian for Hemopurifier® Cancer Trial Operating Expenses Significantly Reduced Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments. Company Updates During the third quarter, a

      2/12/25 4:15:00 PM ET
      $AEMD
      Medical/Dental Instruments
      Health Care